Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

Characteristic Formoterol (n = 57) Budesonide/formoterol (n = 58)
Male/female, n 20/37 22/36
Age, years (range) 43.9 (12–72) 45.9 (13–78)
Race, n (%)   
   Caucasian 39 (68) 37 (64)
   Black 0 1 (2)
   Other 18 (32) 20 (34)
Asthma duration, years (range) 20 (1–65) 22.5 (0–54)
Acute severe asthma exacerbations in the 12 months before study entry   
   Number (%) of patients with event 56 (98) 54 (93)
   Mean number of events (range) 6.3 (1–30) 6.4 (1–40)
Duration of current asthma exacerbation, n   
   <6 hours 2 2
   6–12 hours 4 1
   12–24 hours 4 11
   >24 hours 47 43
FEV1, L (range) 1.15 (0.7–2.0) 1.12 (0.6–1.9)
FEV1, % of predicted normal (range) 41 (30–55) 40 (26–55)
Reversibility, % of predicted normal (range) 2.4 (-8 to +8) 2.1 (-7 to +8)
Reversibility, % of baseline (range) 5.8 (-18 to +23) 5.5 (-16 to +20)
Number (%) of patients prescribed long-acting β2-agonist at entry 4 (7) 6 (10)
Number (%) of patients prescribed ICS at entrya 16 (28) 17 (29)
ICS at entry, μg (range) 768 (160–2560) 624 (100–2400)
  1. All values are presented as absolute numbers or as means, except asthma duration, for which the median is given. aDose of inhaled corticosteroid (budesonide equivalents) in patients receiving inhaled corticosteroid. FEV1 = forced expiratory volume in 1 second; ICS = inhaled corticosteroids.